The IMPACT-CABG trial: A multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy

Abstract Objectives The IMPACT-CABG trial is the first North American multicenter phase II randomized study of intramyocardial delivery of autologous CD133+ stem cells in patients with chronic ischemic cardiomyopathy undergoing coronary artery bypass grafting. The primary objective was to demonstrat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of thoracic and cardiovascular surgery 2016-12, Vol.152 (6), p.1582-1588.e2
Hauptverfasser:	Noiseux, Nicolas, MD, MSc, Mansour, Samer, MD, Weisel, Richard, MD, Stevens, Louis-Mathieu, MD, PhD, Der Sarkissian, Shant, PhD, Tsang, Katherine, RN, MN, Crean, Andrew M., MRCP, Larose, Eric, MD, Li, Shu-Hong, MD, Wintersperger, Bernd, MD, Vu, Minh Quan, MD, Prieto, Ignacio, MD, Li, Ren-Ke, MD, PhD, Roy, Denis Claude, MD, Yau, Terrence M., MD, MSc
Format:	Artikel
Sprache:	eng
Schlagworte:	AC133 Antigen Aged Cardiothoracic Surgery CD133+ cells Coronary Artery Bypass - methods Female Humans ischemic cardiomyopathy Magnetic Resonance Imaging Male Middle Aged Myocardial Ischemia - surgery myocardial repair North America randomized clinical trial stem cell therapy Stem Cell Transplantation - methods Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!